0001966126

IPO filing research

NuvOx Therapeutics, Inc.

Pharmaceutical Preparations · NUOX

ipo amended NYSE American S-1

NuvOx Therapeutics, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-07-17. Current deal snapshot: exchange NYSE American.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Price $7.00 · Range $6.00 to $8.00 · 2,860,000 shares

Common Stock of NuvOx Therapeutics, Inc. · Exchange NYSE American · Ticker NUOX · Over-allotment 429,000 · Use of proceeds Proceeds will be used for general corporate purposes. · Underwriters ThinkEquity

NuvOx Therapeutics, Inc. faces significant regulatory, clinical, and operational risks in its pursuit of FDA and international approvals for its product candidate NanO2. The company highlights uncertainties in obtaining and maintaining regulatory approvals across jurisdictions, ongoing compliance obligations, and potential delays or rejections due to evolving regulatory requirements. Clinical trials are emphasized as costly, time-consuming, and prone to delays, with reliance on third-party contractors and investigators adding complexity. The company also underscores dependencies on licensed technologies, particularly from the University of Arkansas, and challenges in manufacturing process validation. Failure to navigate these risks could impact commercialization and profitability.

2026-07-17 · 0001213900-26-079095

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2025-05-06 · 0001213900-25-040249

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

2025-04-08 · 0001213900-25-029981

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

2024-12-23 · 0001213900-24-111966

Comparable Deals

17 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 17 using nearest neighbors.

Showing top 8 by similarity.

-8.2%

Median day-1

47%

Above issue

-2.1%

Median week-1

-20.9%

Downside (p10)

Kardigan, Inc. KARD

2026-06-18 $400M Day 1: +37.5% Wk 1: +41.1%

same SICrecent IPO

Parabilis Medicines, Inc. PBLS

2026-06-10 $670M Day 1: +58.0% Wk 1: +30.2%

same SICrecent IPO

Seaport Therapeutics, Inc. SPTX

2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%

same SICrecent IPO

Avalyn Pharma Inc. AVLN

2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%

same SICrecent IPO

First Tracks Biotherapeutics, Inc. TRAX

2026-04-20 - Day 1: -9.3% Wk 1: -11.5%

same SICrecent IPO

Kailera Therapeutics, Inc. KLRA

2026-04-17 $625M Day 1: +62.5% Wk 1: +56.7%

same SICrecent IPO

Standard Nuclear, Inc. STDN

2026-07-16 $150M Day 1: -8.2% Wk 1: -24.9%

same SIC grouprecent IPO

Generate Biomedicines, Inc. GENB

2026-02-27 $400M Day 1: -20.9% Wk 1: -22.2%

same SICrecent IPO

Recent News

No recent news stored for this issuer.